“The positive results could drive physician adoption when scheduling colonoscopies for hard-to-prepare patients going forward,” noted an H.C. Wainwright & Co. report.
Motus GI Holdings Inc.’s (MOTS:NASDAQ) Pure-Vu GEN2 system, which cleans the colon during colonoscopy, generated positive, statistically significant trial results, reported H.C. Wainwright & Co. analyst Yi Chen in a May 25th research note.
Pure-Vu GEN2 consists in part of an oversleeve that covers a colonoscope. Via irrigation, suction, and navigation, the foot pedal-operated device cleans the colon walls, allowing the gastroenterologist clearer visibility inside the organ.
The use of Pure-Vu in patients with poor bowel preparation boosted the adequate preparation rate for colonoscopy to 97.7% from the 31.8% rate (p<0.0001) the participants achieved with the prescribed prep before Pure-Vu.
Before the colonoscopy, in which Pure-Vu was tested, patients were tasked with following a two-day low fiber diet, switching to a liquid diet once they started the bowel prep, and drinking 300 milliliters of a combination of sodium picosulfate and magnesium citrate.
Pure-Vu preparation was shown to be at the level required for an effective colonoscopy. These topline data are from the efficacy and safety trial conducted in the European Union.
Get Our Free Metatrader 4 Indicators – Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
Get our Weekly Commitment of Traders Reports - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
“The relative improvement [in the adequate bowel preparation rate] of over 200% is significant,” Chen commented. “The positive [study] results could drive physician adoption when scheduling colonoscopies for hard-to-prepare patients going forward.”
The efficacy of Pure-Vu means that if it is used in patients who inadequately prep before a colonoscopy, they will not have to be admitted for intensive colon cleaning and will not have to undergo repeat colonoscopies, Chen pointed out. Not having to undergo either procedure eliminates the associated stress on patients and reduces costs to the health care system.
H.C. Wainwright has a Buy rating and a $1.50 per share price target on Motus, the stock of which is trading now at around $0.26 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees, or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in the securities mentioned. Directors, officers, employees, or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed, medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures for H.C.WainWright & CO, Motus GI Holdings, Inc., May 25, 2022
H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Yi Chen, Ph.D. CFA, Raghuram Selvaraju, Ph.D. and Boobalan Pachaiyappan, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Motus GI Holdings, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of April 30, 2022 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Motus GI Holdings, Inc. Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The Firm or its affiliates did not receive compensation from Motus GI Holdings, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
The Firm does not make a market in Motus GI Holdings, Inc. as of the date of this research report.
The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously.
H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.
H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.
The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.